Pretax income is the income that a company earns before paying income taxes. Supernus Pharmaceuticals's pretax income for the
three
months ended in Dec. 2023 was $1.0 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $2.8 Mil.
Supernus Pharmaceuticals's pretax margin was 0.60%.
During the past 13 years, Supernus Pharmaceuticals's highest Pretax Margin was 37.55%. The lowest was -11.11%. And the median was 18.03%.
Supernus Pharmaceuticals Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Supernus Pharmaceuticals's Pre-Tax Income
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Pre-Tax Income falls into.
Supernus Pharmaceuticals Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Supernus Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (NAS:SUPN) Pre-Tax Income Explanation
Supernus Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Supernus Pharmaceuticals's highest Pretax Margin was 37.55%. The lowest was -11.11%. And the median was 18.03%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Supernus Pharmaceuticals (Supernus Pharmaceuticals) Business Description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SUPN has been successfully added to your 